Merck
  • Home
  • Search Results
  • Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin.

Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (2015-01-18)
Kit Frederiksen, Richard H Guy, Karsten Petersson
ABSTRACT

Polymeric film-forming systems (FFSs) are potential drug delivery systems for topical application to the skin. The FFSs form thin and transparent polymeric films in situ upon solvent evaporation. Their application convenience and cosmetic attributes, superior to conventional semi-solids, may offer improved patient compliance. This study represents the first phase of an investigation into the use of FFSs for prolonged dermal drug delivery. FFS formulations were distinguished based on their ability to sustain the release of betamethasone 17-valerate (BMV) in vitro over 72 h. The effect of film-forming polymer (hydrophilic: hydroxypropyl cellulose (Klucel™ LF); hydrophobic: polymethacrylate copolymers (Eudragit® NE and Eudragit® RS), and polyacrylate copolymer (Dermacryl® 79) was first determined, and then the impact of incorporation of plasticisers (triethyl citrate, tributyl citrate, and dibutyl sebacate) was examined. The Klucel film released a significantly higher amount of BMV than the hydrophobic FFS, 42 versus 4 μg/cm(2), respectively. The release was increased when a plasticiser was incorporated, and with higher enhancement ratios achieved with the more lipophilic plasticisers. In conclusion, the results show that FFSs can sustain drug release (hence representing useful systems for prolonged dermal therapy) and emphasise the importance of the formulation on drug delivery, with the type of polymer being of greatest significance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methyl methacrylate, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
Methyl methacrylate, 99%, stabilized
Supelco
Triethyl citrate, analytical standard
Supelco
Triethyl citrate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Triethyl citrate, ≥99%, FCC, FG
Sigma-Aldrich
Tributyl citrate, ≥97.0%
Sigma-Aldrich
Triethyl citrate, ≥98.0% (GC)
USP
Tributyl citrate, United States Pharmacopeia (USP) Reference Standard
Methyl methacrylate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Triethyl citrate, Vetec, reagent grade, 98%
Sigma-Aldrich
Dibutyl sebacate, technical grade
Supelco
Dibutyl sebacate, Selectophore, ≥97.0%
Sigma-Aldrich
Dibutyl sebacate, ≥97.0% (GC)
Sigma-Aldrich
Sodium acetate trihydrate, BioUltra, ≥99.5% (NT)
Supelco
Dibutyl sebacate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sodium acetate trihydrate, Vetec, reagent grade, 99%
Supelco
Dibutyl sebacate, analytical standard
Sigma-Aldrich
Sodium acetate trihydrate, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Sodium acetate trihydrate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E262, 99.0-101.0% (calc. to the dried substance), ≤0.00002% Al
Sigma-Aldrich
Sodium acetate trihydrate, ACS reagent, ≥99%
Sigma-Aldrich
Sodium acetate trihydrate, BioXtra, ≥99.0%
Sigma-Aldrich
Sodium acetate trihydrate, meets USP testing specifications